American Financial Group’s Keros Therapeutics KROS Stock Holding History

American Financial Group’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$112K	Hold	10,105	–	–	0.04%	69
2025 Q4	$206K	Hold	10,105	–	–	0.07%	60
2025 Q3	$160K	Hold	10,105	–	–	0.06%	56
2025 Q2	$135K	Hold	10,105	–	–	0.05%	58
2025 Q1	$103K	Hold	10,105	–	–	0.04%	57
2024 Q4	$160K	Hold	10,105	–	–	0.07%	57
2024 Q3	$587K	Hold	10,105	–	–	0.25%	51
2024 Q2	$462K	Hold	10,105	–	–	0.2%	53
2024 Q1	$669K	Hold	10,105	–	–	0.25%	52
2023 Q4	$402K	Hold	10,105	–	–	0.15%	63
2023 Q3	$322K	Hold	10,105	–	–	0.11%	71
2023 Q2	$406K	Hold	10,105	–	–	0.13%	72
2023 Q1	$431K	Hold	10,105	–	–	0.13%	71
2022 Q4	$485K	Hold	10,105	–	–	0.16%	72
2022 Q3	$380K	Hold	10,105	–	–	0.13%	76
2022 Q2	$279K	Hold	10,105	–	–	0.09%	81
2022 Q1	$550K	Hold	10,105	–	–	0.17%	69
2021 Q4	$591K	Hold	10,105	–	–	0.16%	67
2021 Q3	$400K	Hold	10,105	–	–	0.11%	76
2021 Q2	$429K	Buy	+10,105	New	+$547K	0.11%	72

Other funds holding KROS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

American Financial Group's KROS Position: Q1 2026 in Review

American Financial Group held its Keros Therapeutics (KROS) position steady in Q1 2026 at 10,105 shares worth $112K. The position accounts for 0.04% of the portfolio, ranked #69.

American Financial Group first reported a position in KROS in Q2 2021 and has held it in 20 quarters since. The position peaked at $669K in Q1 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

American Financial Group held 10,105 shares of Keros Therapeutics worth $112K as of Q1 2026.
American Financial Group left its Keros Therapeutics share count unchanged in Q1 2026.
Keros Therapeutics made up 0.04% of American Financial Group's portfolio in Q1 2026, its #69 holding.
American Financial Group first reported a position in Keros Therapeutics in Q2 2021 and has held it in 20 quarters since.
American Financial Group's Keros Therapeutics position peaked at $669K in Q1 2024.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on American Financial Group's 13F filing for Q1 2026, filed 13 May 2026.